The findings in this study provide a clinical rationale for the combined use of the CX3CR1 inhibitor JMS-17-2 and the p-AKT inhibitor capivasertib in PTEN-deficient prostate cancer. This evidence concerns the gene PTEN and prostate carcinoma.